Last reviewed · How we verify
Inotrope
Inotrope is a Small molecule drug developed by Tufts Medical Center. It is currently in Phase 2 development. Also known as: Vasopressor, Primacor.
Inotrope is a small molecule drug, classified as a positively inotropic agent, which increases the strength of muscular contractions. It is being studied in clinical trials for various conditions, including heart failure, acute decompensated heart failure, and aortic valve stenosis.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Inotrope |
|---|---|
| Also known as | Vasopressor, Primacor |
| Sponsor | Tufts Medical Center |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Effect of Targeted Fluid Therapy on Postoperative Cognitive Dysfunction. (NA)
- Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure (NA)
- The PROTECT-HIE Trial (PHASE2)
- Cooling in Mild Encephalopathy (PHASE3)
- Impact of Intraoperative Hemodynamic Instability on Outcomes in Cardiac Surgery
- G- Forces On Retrieved ChildrEn Pilot Study
- Levosimendan in Acute Decompensated Heart Failure (PHASE2, PHASE3)
- Evaluation of Perioperative Myocardial Injury in Patients Undergoing Below-Knee Lower Extremity Surgery
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Inotrope CI brief — competitive landscape report
- Inotrope updates RSS · CI watch RSS
- Tufts Medical Center portfolio CI
Frequently asked questions about Inotrope
What is Inotrope?
Who makes Inotrope?
Is Inotrope also known as anything else?
What development phase is Inotrope in?
Related
- Manufacturer: Tufts Medical Center — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Vasopressor, Primacor
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing